Showing 1991-2000 of 2526 results for "".
- Study Finds Recycling of the Eye’s Light Sensors Is Faulty in Progressive Blindness of Older Adultshttps://modernod.com/news/study-finds-recycling-of-the-eyes-light-sensors-is-faulty-in-progressive-blindness-of-older-adults/2479323/With the National Eye Institute reporting that about 11 million older adults in the US endure age-related macular degeneration (AMD), University of Maryland School of Medicine (UMSOM) researchers are starting to understand what goes wrong in the disease, in order to develop new therapies to tre
- Johnson & Johnson Vision Announces Launch of Tecnis Synergy and Tecnis Synergy Toric II PC-IOLs in US and Canadahttps://modernod.com/news/johnson-johnson-vision-announces-launch-of-tecnis-synergy-and-tecnis-synergy-toric-ii-pc-iols-in-us-and-canada/2479320/Johnson & Johnson Vision announced the availability of Tecnis Synergy and Tecnis Synergy Toric II IOLs in the United States and Canada. These next-generation PC-IOLs combine the best of extended depth of focus and multifocal technologies to deliver the widest range of continuous vision and th
- Belkin Laser Appoints Andrew Webb as Chief Commercial Officerhttps://modernod.com/news/belkin-laser-appoints-andrew-webb-as-chief-commercial-officer/2479316/Israel-based medical device company Belkin Laser has announced the appointment of Andrew Webb as Chief Commercial Officer. Under Mr. Webb’s guidance, the company’s commercial and go-to-market strategy will be rolled out in anticipation of a controlled launch in
- Noveome Biotherapeutics Announces Preliminary Results of its Phase 1 Trial Evaluating Intranasal Delivery of ST266 In Glaucoma Suspect Patientshttps://modernod.com/news/noveome-biotherapeutics-announces-preliminary-results-of-its-phase-1-trial-evaluating-intranasal-delivery-of-st266-in-glaucoma-suspect-patients/2479275/Noveome Biotherapeutics announced preliminary results of a phase 1 open label clinical trial to establish the safety of ST266 when delivered intranasally in glaucoma suspect patients. The trial was conducted at the University of Pennsylvania by Ahmara Ross, MD, PhD, and Kenneth Shindler, MD, PhD,
- Glaukos Announces Australia’s TGA Regulatory Approval for Preserflo MicroShunthttps://modernod.com/news/glaukos-announces-australias-tga-regulatory-approval-for-preserflo-microshunt/2479276/Glaukos Corporation announced that the Therapeutic Goods Administration (TGA) of Australia has granted regulatory approval for the Preserflo MicroShunt intended for the reduction of IOP in eyes of patients with primary open-angle glaucoma where IOP remains uncontrollable while on maximum tolerate
- Lighthouse Guild Starts Construction on New Technology Centerhttps://modernod.com/news/lighthouse-guild-starts-construction-on-new-technology-center/2479265/Lighthouse Guild has started construction on a Technology Center that will be the largest, premier assistive technology resource in the United States, according to a news release. Designed for people who are visually impaired and for all people who are using technology in order to help them, it i
- Scientists Use Video Games to Shed Light on the Link Between Motor Activity and Visionhttps://modernod.com/news/scientists-use-video-games-to-shed-light-on-the-link-between-motor-activity-and-vision/2479266/It’s a well established fact—and intuitive truth—that vision guides movement, and that information flows readily from the visual cortex to motor centers. However, the inverse relation is far less well understood. Does engaging in movement affect how our vision is processed? Three researchers from
- Kala Pharmaceuticals Announces Eysuvis Now Covered by OptumRxhttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-by-optumrx/2479263/Kala Pharmaceuticals announced that OptumRx, one of the largest pharmacy benefit managers (PBM) in the United States, has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 21, 2021. “We are pleased to announce
- Salvat Completes Phase 3 Clinical Trials of its New Ophthalmic Corticosteroid Nanoemulsionhttps://modernod.com/news/salvat-completes-phase-3-clinical-trials-of-its-new-ophthalmic-corticosteroid-nanoemulsion/2479254/Salvat has completed the phase 3 clinical trials in the US for its drug candidate for the treatment of ocular inflammation and pain after cataract surgery. The clinical trials started in 2020 and include 400 adult patients who had recently undergone cataract surgery in 50 US hospitals. Res
- Neurophth Therapeutics and Hopstem Biotechnology Partner to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for Ocular Diseaseshttps://modernod.com/news/neurophth-therapeutics-and-hopstem-biotechnology-partner-to-develop-human-induced-pluripotent-stem-cell-derived-therapies-for-ocular-diseases/2479248/Neurophth Biotechnology and Hopstem Biotechnology announced a strategic partnership aiming to provide human iPSC-derived cell therapy for ocular diseases. The partnership leverages Neurophth’s experience in global gene/cell therapy drugs development and understanding of ophthalmic di